Here’s a game-changer for millions of Australians: Wegovy, a groundbreaking medication for weight loss, is set to become more accessible through the Pharmaceutical Benefits Scheme (PBS). But here’s where it gets controversial—while this move aims to tackle obesity and prevent type 2 diabetes, it raises questions about the role of medication in addressing lifestyle-related health issues. Let’s dive in.
The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended that Wegovy (semaglutide) be subsidized through the PBS for adults with established cardiovascular disease and obesity. This decision comes after Diabetes Australia’s Group CEO, Justine Cain, welcomed the recommendation and comments from Federal Health Minister Mark Butler, who indicated the government would collaborate with manufacturer Novo Nordisk to make the medication more affordable.
Why does this matter? Supporting individuals in their weight loss journey is a critical part of preventing type 2 diabetes. While genetics and family history play a role, a staggering 58% of type 2 diabetes cases can be prevented or delayed. Affordable access to weight loss medications like Wegovy is a powerful tool in this fight. But this is the part most people miss—it’s not just about the medication; it’s about addressing the broader factors contributing to obesity and chronic conditions.
The PBAC’s published recommendation specifies that the subsidy should be provided for adults with established cardiovascular disease (eCVD) and obesity, who have already experienced a cardiovascular event such as a heart attack, stroke, or symptomatic peripheral arterial disease. This targeted approach aims to help those at the highest risk.
Led by Diabetes Australia, the Diabetes Alliance made a joint submission to PBAC’s November 2025 meeting, emphasizing the importance of access to GLP-1 RA medicines like semaglutide for treating obesity. Their advocacy highlights the increased risk of chronic conditions, including type 2 diabetes and heart disease, associated with obesity. Justine Cain praised the positive reception of the sector’s advice, calling the recommendation a helpful step in managing obesity and reducing chronic disease rates in Australia.
But here’s the bold question: Is relying on medications like Wegovy a sustainable solution, or should we focus more on preventive measures like diet, exercise, and public health initiatives? With over 1.3 million Australians living with type 2 diabetes and another 2 million at risk, this debate is more relevant than ever. What’s your take? Let’s spark a conversation in the comments—do you think this is a step in the right direction, or are we missing the bigger picture?
